contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


alligator-announces-evaluation-and-option-agreement-covering-rubytm-antibody-format

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Alligator Bioscience is a research-based biotechnology company that uses patented technology to develop biological drug candidates in inflammation and cancer. The company is active in the former part of the drug development chain. Alligator Bioscience has a global technology platform and is active in a rapidly growing segment of the pharmaceutical market - protein drugs. The company was founded in 2001 and is headquartered in Lund, Sweden.

Alligator Bioscience

Lund, Sweden – 2 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Alligator has entered into an evaluation and option agreement with an infectious disease...

<div class="mfn-body">Lund, Sweden – 2 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Alligator has entered into an evaluation and option agreement with an infectious disease company regarding its proprietary RUBY™ bispecific antibody format.The evaluation and option agreement relates to the application of the RUBYTM platform in specific infectious diseases. The agreement includes a two-year evaluation period and provides the counterparty with an exclusive option to negotiate a license agreement based on the evaluation of certain antibodies in the RUBY™ bispecific antibody format. An option fee in installments of USD 75,000 is payable to Alligator.<blockquote>“While our primary focus remains firmly on advancing mitazalimab into Phase 3 and securing a commercial partnership, we continue to explore opportunities to unlock additional value from our proprietary antibody platforms,” said Søren Bregenholt, CEO of Alligator Bioscience. “This RUBY™ agreement exemplifies how our innovation engine can foster innovative products and at the same time generate non-dilutive financing to support our long-term strategy.”</blockquote><hr></div><div class="mfn-footer mfn-0c892b90f815">For further information, please contact:<hr>Søren Bregenholt, CEO E-mail:&nbsp;<a rel="noopener" href="mailto:sbr@alligatorbioscience.com?subject=Alligator%20Bioscience%20to%20Present%20Additional%20data%20of%20ATOR-1017%20First-in-Human%20Study%20via%20poster%20presentation%20at%20ASCO%20Annual%20Meeting%202022">soren.bregenholt@alligatorbioscience.com</a> Phone: +46 (0) 46 540 82 00</div><div class="mfn-footer mfn-a4bddb8ecc24"><hr>The information was submitted for publication, through the agency of the contact person set out above, at 4:00 p.m. CEST on 2 September 2025.</div><div class="mfn-footer mfn-about mfn-76021e509ec4">About Alligator Bioscience<hr>Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company’s lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.For more information, please visit&nbsp;<a rel="noopener" href="https://www.alligatorbioscience.se/en">alligatorbioscience.com</a>.</div><div class="mfn-footer mfn-c6b2483654a4">About RUBY™<hr>RUBY™ is Alligator’s proprietary format for creating bispecific antibodies—designed to bind two targets at once and to provide high stability and strong therapeutic potential. The format enables rapid, plug-and-play development of advanced immunotherapies.The value of RUBY™ is reflected in Orion Corporation’s continued commitment to two RUBY™-based antibodies, for which future financial obligations were acquired by Orion in 2024.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/ada1cbe9-d347-46ce-b32a-aaee4ba15964/alligator-announces-evaluation-and-option-agreement-covering-ruby-antibody-format.pdf" class="mfn-generated mfn-primary">Alligator announces evaluation and option agreement covering RUBY™ antibody format</a></div>

Alligator announces evaluation and option agreement covering RUBY™ antibody format